Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

22.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
22.3K
Gene Therapy00:59

Gene Therapy

4.5K
4.5K
CRISPR01:59

CRISPR

46.7K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
46.7K
Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

5.7K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
5.7K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

3.2K
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An effective tumor-inhibiting siRNA delivery platform.

Biochemical and biophysical research communications·2026
Same author

Systemic dual delivery of a tumor-inhibiting plasmid expressing p16 and shRaf.

Biochemical and biophysical research communications·2025
Same author

A Facile and Promising Delivery Platform for siRNA to Solid Tumors.

Molecules (Basel, Switzerland)·2024
Same author

Delivery of mRNA with Histidine-Lysine Peptides.

Methods in molecular biology (Clifton, N.J.)·2024
Same author

pH-Dependent Non-Covalent Release of Chemotherapy from Carriers.

Discovery medicine·2024
Same author

Cytokine Signatures for Lung Cancer Diagnosis in African American Populations.

Journal of personalized medicine·2024

Related Experiment Video

Updated: May 6, 2026

Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs
09:11

Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs

Published on: June 14, 2012

29.1K

Zinc Finger Nucleases: Tailor-made for Gene Therapy.

S-T Chou1, Qixin Leng, A J Mixson

  • 1Department of Pathology, University of Maryland School of Medicine, MSTF Building, 10 South Pine Street, Baltimore, MD 21201, USA ; Department of Chemical and Biomolecular Engineering, University of Maryland, College Park, MD 20742.

Drugs of the Future
|October 25, 2013
PubMed
Summary

Zinc finger nuclease (ZFN) gene therapy offers a promising approach for genetic diseases. This technology enables precise gene editing in various cells and animal models, with ongoing clinical trials for cancer and HIV.

More Related Videos

Mouse Genome Engineering Using Designer Nucleases
12:04

Mouse Genome Engineering Using Designer Nucleases

Published on: April 2, 2014

31.9K
Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells
12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

10.0K

Related Experiment Videos

Last Updated: May 6, 2026

Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs
09:11

Genome Editing with CompoZr Custom Zinc Finger Nucleases ZFNs

Published on: June 14, 2012

29.1K
Mouse Genome Engineering Using Designer Nucleases
12:04

Mouse Genome Engineering Using Designer Nucleases

Published on: April 2, 2014

31.9K
Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells
12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

10.0K

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Background:

  • Genome editing using zinc finger nucleases (ZFNs) is applicable to eukaryotic cells and animal models.
  • ZFNs enable targeted gene manipulation via DNA breaks, leading to functional gene alterations.

Purpose of the Study:

  • To review recent advances in ZFN gene therapy.
  • To discuss potential risks associated with ZFN technology.

Main Methods:

  • Site-specific double-strand DNA breaks induced by engineered ZFNs.
  • Non-homologous end joining (NHEJ) or homologous recombination (HR) repair pathways.
  • Systemic viral delivery for in vivo gene editing.

Main Results:

  • ZFNs demonstrated successful correction of Factor IX in mouse hemophilia models.
  • Phase I clinical trials are underway for glioblastoma and HIV.
  • ZFNs offer persistent gene modification, potentially overcoming limitations of other therapies.

Conclusions:

  • ZFN gene therapy shows significant therapeutic potential for genetic diseases, infectious diseases, and oncology.
  • The technology provides flexibility for gene function modulation.
  • Ongoing research and clinical trials are crucial for evaluating safety and efficacy.